HspE7 plus adjuvant: Interim Phase I data

Data from the second cohort of 4 patients in an open-label, U.S. Phase I trial showed that 500 µg of HspE7 plus an escalated dose of Poly-ICLC adjuvant was safe. The study is enrolling 24 patients and...